<DOC>
	<DOCNO>NCT01584466</DOCNO>
	<brief_summary>Comorbid substance abuse lead many deleterious effect medical comorbidities nonadherence , one problematic issue . People schizophrenia substance use disorder ( SUDs ) increase risk nonadherence compare use alcohol illicit drug . The investigator propose new market injectable antipsychotic many benefit available long act injectable agent would beneficial dually diagnose population may represent specific schizophrenia subpopulation long act agent may consider important therapeutic option .</brief_summary>
	<brief_title>Long Acting Paliperidone Dually Diagnosed People With Schizophrenia : An Open-label Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Be age 18 64 Either gender Any race Meet DSMIVTR criterion Schizophrenia Schizoaffective Disorder . Alcohol and/or cannabis use define DSMIV diagnosis abuse , dependence regular use define 3 time per week past year Agree take use birth control study . Previous lack response serious adverse event risperidone paliperidone . Currently long act injectable antipsychotic . A score less 10 Evaluation Sign Consent ( ESC ) . Medical illness , may compromise safe study participation . Pregnant lactating female . QTc interval &gt; 450 millisecond male &gt; 470 millisecond female Currently acamprosate , naltrexone disulfiram .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Substance Abuse</keyword>
</DOC>